HK1178149A1 - 吡唑- -基-雜環基-甲酰胺化合物及其使用方法 - Google Patents

吡唑- -基-雜環基-甲酰胺化合物及其使用方法

Info

Publication number
HK1178149A1
HK1178149A1 HK13105060.9A HK13105060A HK1178149A1 HK 1178149 A1 HK1178149 A1 HK 1178149A1 HK 13105060 A HK13105060 A HK 13105060A HK 1178149 A1 HK1178149 A1 HK 1178149A1
Authority
HK
Hong Kong
Prior art keywords
pyrazol
heterocyclyl
methods
carboxamide compounds
carboxamide
Prior art date
Application number
HK13105060.9A
Other languages
English (en)
Inventor
Xiaojing Wang
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44227838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1178149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1178149A1 publication Critical patent/HK1178149A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK13105060.9A 2010-04-07 2013-04-26 吡唑- -基-雜環基-甲酰胺化合物及其使用方法 HK1178149A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32158810P 2010-04-07 2010-04-07
PCT/EP2011/055300 WO2011124580A1 (en) 2010-04-07 2011-04-06 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Publications (1)

Publication Number Publication Date
HK1178149A1 true HK1178149A1 (zh) 2013-09-06

Family

ID=44227838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105060.9A HK1178149A1 (zh) 2010-04-07 2013-04-26 吡唑- -基-雜環基-甲酰胺化合物及其使用方法

Country Status (20)

Country Link
US (3) US8436001B2 (zh)
EP (1) EP2556066B1 (zh)
JP (2) JP6161537B2 (zh)
KR (1) KR101464060B1 (zh)
CN (1) CN102933572B (zh)
AU (1) AU2011237936A1 (zh)
BR (1) BR112012025480A2 (zh)
CA (1) CA2794801C (zh)
CL (1) CL2012002782A1 (zh)
CO (1) CO6630133A2 (zh)
CR (1) CR20120469A (zh)
EA (1) EA201290957A1 (zh)
ES (1) ES2601004T3 (zh)
HK (1) HK1178149A1 (zh)
IL (1) IL222227A0 (zh)
MA (1) MA34234B1 (zh)
MX (1) MX2012011533A (zh)
PE (1) PE20130405A1 (zh)
SG (1) SG184475A1 (zh)
WO (1) WO2011124580A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6120861B2 (ja) * 2011-09-27 2017-04-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
KR20150013548A (ko) 2012-05-21 2015-02-05 노파르티스 아게 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014048939A1 (en) * 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
PE20160532A1 (es) * 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
NZ631142A (en) * 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CA2929316C (en) * 2013-11-08 2021-12-28 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
KR20160127140A (ko) * 2014-03-18 2016-11-02 에프. 호프만-라 로슈 아게 옥세판-2-일-피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016123627A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
EP3286181B1 (en) * 2015-04-22 2021-01-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
EP3532465B1 (en) 2016-10-26 2023-03-01 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN110452180A (zh) * 2019-06-25 2019-11-15 南京普锐达医药科技有限公司 一种合成2-氯-5-氨基-6-嘧啶甲酸乙酯的方法
EP4003990A1 (en) 2019-08-30 2022-06-01 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
CN111087389B (zh) * 2019-12-03 2020-10-27 佳木斯大学 一种用于治疗胶质母细胞瘤的药物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP1409125B1 (en) 2001-07-12 2016-04-20 Reaxa Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
PT1618092E (pt) * 2003-05-01 2010-11-22 Bristol Myers Squibb Co Compostos de pirazol-amida substituídos com arilo úteis enquanto inibidores de cinase
KR20070049655A (ko) * 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
FR2903406B1 (fr) 2006-07-04 2012-08-10 Aventis Pharma Sa Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
US20090318430A1 (en) 2006-07-21 2009-12-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US9206142B2 (en) 2006-10-31 2015-12-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
US8318735B2 (en) * 2006-10-31 2012-11-27 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
CA2691416A1 (en) * 2007-06-22 2008-12-31 Adam Van Opynen An extension for a pipe expander
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
MX2010004876A (es) * 2007-10-29 2010-07-28 Schering Corp Derivados de diamido tiazol como inhibidores de la proteina cinasa.
WO2009058739A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
MX2010004875A (es) * 2007-10-29 2010-05-19 Schering Corp Derivados de tiazol y metodos para utilizarlos.
EP2070916A1 (de) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
NZ586756A (en) 2008-01-22 2012-04-27 Vernalis R&D Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
UY31679A1 (es) 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
WO2009119088A1 (ja) * 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
EP2344474B1 (en) * 2008-09-02 2015-09-23 Novartis AG Picolinamide derivatives as kinase inhibitors
WO2011000020A1 (en) 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
CN102625807B (zh) * 2009-09-08 2016-03-09 霍夫曼-拉罗奇有限公司 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
BR112012009574A2 (pt) 2009-10-22 2019-09-24 Univ Vanderbilt potencializador alostérico de mglura, composições, e métodos de tratamento de disfunção neurológica
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds

Also Published As

Publication number Publication date
JP2013523798A (ja) 2013-06-17
SG184475A1 (en) 2012-11-29
CO6630133A2 (es) 2013-03-01
AU2011237936A1 (en) 2012-10-11
IL222227A0 (en) 2012-12-31
WO2011124580A1 (en) 2011-10-13
JP6161537B2 (ja) 2017-07-12
US20130203732A1 (en) 2013-08-08
ES2601004T3 (es) 2017-02-13
CN102933572A (zh) 2013-02-13
MX2012011533A (es) 2012-12-17
CR20120469A (es) 2012-11-30
EP2556066B1 (en) 2016-10-19
US8436001B2 (en) 2013-05-07
JP2016040281A (ja) 2016-03-24
CN102933572B (zh) 2015-01-07
CL2012002782A1 (es) 2013-01-18
US8669361B2 (en) 2014-03-11
EA201290957A1 (ru) 2013-04-30
KR101464060B1 (ko) 2014-11-20
MA34234B1 (fr) 2013-05-02
BR112012025480A2 (pt) 2020-08-18
US20110251176A1 (en) 2011-10-13
CA2794801C (en) 2019-01-15
US9573943B2 (en) 2017-02-21
EP2556066A1 (en) 2013-02-13
PE20130405A1 (es) 2013-04-10
CA2794801A1 (en) 2011-10-13
US20140128376A1 (en) 2014-05-08
KR20130001309A (ko) 2013-01-03

Similar Documents

Publication Publication Date Title
IL266168A (en) Heteroaryl compounds and methods of their use
HK1243417A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
HK1178149A1 (zh) 吡唑- -基-雜環基-甲酰胺化合物及其使用方法
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2772483A4 (en) 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF
PT2539136T (pt) Poste de barreira e método de fabrico do mesmo
EP2663565A4 (en) HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
ZA201206456B (en) Uses of dgati inhibitors
IL220812A0 (en) Compounds and methods
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
EP2523560A4 (en) CONNECTIONS AND METHODS
IL256026A (en) Treatment methods
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2592997A4 (en) FORCE-FORCE SPECTROMETER AND METHODS OF USE
EP2611791A4 (en) OLIGOOXOPIPERAZINES AND METHODS FOR THEIR PREPARATION AND USE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200401